PM

Professor Maskell

CSL Limited | Non-Executive Director
Professor Maskell has international experience in science and commerce, with a focus in research, academia and entrepreneurship. Prior to this he was senior pro-vice-chancellor at the University of Cambridge in the UK and has also held roles at the University of Oxford, Imperial College London and Wellcome Biotech. Professor Maskell has experience across the private sector, reflecting his passion for the commercialisation of research initiatives. He has co-founded several biotech companies, including Arrow Therapeutics, which was sold to biopharmaceutical company AstraZeneca, and Discuva, which was sold to Summit Therapeutics. He has also served as a Non-Executive Director of Genus Plc, a FTSE 250 company. He is a a Director of the Grattan Institute (since November 2018), Vice-Chancellor of the University of Melbourne (since October 2018), Director of Melbourne Business School (since October 2018), Director of the Group of Eight Limited (since October 2018) and Director of Universities Australia Limited (since October 2018). He is a Member of the Innovation and Development Committee.

Company and Role

Company
Title
Tenure
Since
CSL
CSL Limited
  • Non-Executive Director
2yrs, 11mthAug 2021

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
CSL
CSL Limited
16/02/2401,356N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
CSL
CSL Limited
16/02/24
Exercise
339$284.000$96,276Conversion of securities
CSL
CSL Limited
16/02/24
Buy
339$284.000$96,276Conversion of securities
CSL
CSL Limited
23/08/23
Issued
677$268.978$182,098Issue of securities
CSL
CSL Limited
21/08/23
Exercise
300$266.860$80,058Conversion of securities
CSL
CSL Limited
21/08/23
Buy
300$266.860$80,058Conversion of securities